DRUG · Unmapped registry intervention
Interferon beta-1a (Rebif)
Find medicine records ·
Find other trials using this name
Clinical trial
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
NCT01142466
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Multiple Sclerosis, Relapsing-Remittingunresolved
Interventions
Sponsors & collaborators
Merck KGaA, Darmstadt, Germanylead sponsor
Gesellschaft für Therapieforschung mbHcollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01142466 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.